Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
boston blog main
fda
boston top stories
drugs
alnylam pharmaceuticals
aminolevulinic acid
biotech
boston
detroit blog main
detroit top stories
givosiran
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alprazolam
amgen
bempedoic acid
blueprint medicines
boulder/denver blog main
boulder/denver top stories
cancer
cgrp inhibitors
cholesterol
chronic migraine
colucid pharmaceuticals
companion diagnostic
corticosteroids
detroit
dna sequencing
drug enforcement administration
eli lilly
What
drug
6
×
second
6
×
fda
medicine
new
alnylam
approval
approved
interference
nod
oks
pharmaceuticals
rna
rnai
seek
speedy
act
acute
addresses
ago
allow
best
better
bring
build
cancer
causes
changing
cholesterol
cleared
combo
condition
data
decades
deeper
democrats
dna
eli
emerged
esperion
Language
unset
Current search:
second
×
drug
×
@techdirt.com
2 years ago
Drug Price Negotiation Is A Second-Best Fix. Here's What Will Really Work
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug